Innoviva Inc INVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
-
Innoviva to Participate in Upcoming Investor Conferences
-
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
-
Innoviva Gets FDA Approval for Gonorrhea Drug
Trading Information
- Previous Close Price
- $22.42
- Day Range
- $22.37–23.00
- 52-Week Range
- $16.52–25.15
- Bid/Ask
- $21.50 / $23.85
- Shares Outstanding
- 73.81M
- Market Cap
- $1.67B
- Volume/Avg
- 564,707 / 770,122
Key Statistics
- Price/Earnings (Normalized)
- 11.38
- Price/Sales
- 4.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 1.34%
Company Profile
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 159
- Website
- https://www.inva.com
Competitors
Valuation
|
Metric
|
INVA
|
AZN
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.38 | 19.54 | 8.56 |
Price/Book Value | 1.25 | 5.81 | 1.66 |
Price/Sales | 4.88 | 4.66 | 2.37 |
Price/Cash Flow | 9.05 | 17.69 | 8.75 |
Price/Earnings
INVA
AZN
PFE
Financial Strength
|
Metric
|
INVA
|
AZN
|
PFE
|
|---|---|---|---|
Quick Ratio | 19.27 | 0.70 | 0.85 |
Current Ratio | 21.13 | 0.91 | 1.25 |
Interest Coverage | 33.86 | 8.17 | 3.73 |
Quick Ratio
INVA
AZN
PFE
Profitability
|
Metric
|
INVA
|
AZN
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 10.00% | 9.16% | 8.40% |
Return on Equity (Normalized) | 15.33% | 22.59% | 19.47% |
Return on Invested Capital (Normalized) | 10.73% | 14.71% | 12.80% |
Return on Assets
INVA
AZN
PFE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bpjyqjjrp | Ymkdspd | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zwffqyhq | Xxmmxh | $64B | |||
| argenx SE ADR
ARGX
| Wndthtvn | Xhpf | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Njtwsfzg | Nhgpm | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Xdhtyrsnm | Qdlbnn | $24B | |||
| BioNTech SE ADR
BNTX
| Rtyqxslbm | Srybv | $23B | |||
| Incyte Corp
INCY
| Ydxhmrfh | Dchg | $22B | |||
| Moderna Inc
MRNA
| Lvlgjzvs | Yxcqn | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Srvvzvm | Rst | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Vxplnykp | Wkskl | $13B |
United States